Breast cancer in young women and prognosis: How important are proliferation markers?

[1]  Beicheng Sun,et al.  Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer , 2017, Medicine.

[2]  R. Rouzier,et al.  Breast cancer in young women: Pathologic features and molecular phenotype. , 2016, Breast.

[3]  Rulla M Tamimi,et al.  Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Holmberg,et al.  Long-term outcome in young women with breast cancer: a population-based study , 2016, Breast Cancer Research and Treatment.

[5]  Jingjing Cui,et al.  Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers. , 2016, American journal of translational research.

[6]  S. Swain,et al.  Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age , 2015, Advances in Therapy.

[7]  Jing Yan,et al.  Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer. , 2015, International journal of clinical and experimental medicine.

[8]  A. Zetterberg,et al.  A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer. , 2015, Annals of diagnostic pathology.

[9]  R. Shui,et al.  Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China , 2015, PloS one.

[10]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  G. Di,et al.  Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China , 2015, BMC Cancer.

[12]  L. Holmberg,et al.  Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study , 2015, Acta oncologica.

[13]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[14]  L. Akslen,et al.  Evaluation of Ki67 Expression across Distinct Categories of Breast Cancer Specimens: A Population-Based Study of Matched Surgical Specimens, Core Needle Biopsies and Tissue Microarrays , 2014, PloS one.

[15]  A. Luini,et al.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.

[16]  J. Bergh,et al.  Multi‐level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients , 2014, Molecular oncology.

[17]  M. Fernö,et al.  The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer , 2013, PloS one.

[18]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Cheng Lu,et al.  Prognostic value of cyclin E expression in breast cancer: a meta-analysis , 2013, Tumor Biology.

[21]  G. Fountzilas,et al.  Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. , 2013, Anticancer research.

[22]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Anais Malpica,et al.  Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer , 2012, Histopathology.

[24]  D. Rahardja,et al.  Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer , 2012, British Journal of Cancer.

[25]  C. Sotiriou,et al.  Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling , 2012, Clinical Cancer Research.

[26]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[27]  Peter A Fasching,et al.  Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.

[28]  A. Luini,et al.  Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[30]  L. Holmberg,et al.  Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment , 2009, PloS one.

[31]  R. Aft,et al.  Patient and tumor characteristics associated with increased mortality in young women (≤40 years) with breast cancer , 2009, Journal of surgical oncology.

[32]  Gordon B Mills,et al.  Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer , 2009, Clinical Cancer Research.

[33]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[34]  D. Jeffe,et al.  Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. , 2009, Journal of the American College of Surgeons.

[35]  T. Nielsen,et al.  The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. , 2008, Human pathology.

[36]  J. Marks,et al.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[38]  H. Nevanlinna,et al.  Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut‐off values? , 2007, Histopathology.

[39]  W. Han,et al.  Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Sapino,et al.  Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure , 2006, Virchows Archiv.

[41]  K. Hunt,et al.  Cyclin E as a prognostic and predictive marker in breast cancer. , 2005, Seminars in cancer biology.

[42]  Douglas G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK). , 2005, European journal of cancer.

[43]  T. Lindahl,et al.  Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. , 2003, Carcinogenesis.

[44]  M. Fernö,et al.  Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node‐negative breast cancer , 2003, International journal of cancer.

[45]  T. Hwang,et al.  Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients , 2003, Pathology international.

[46]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[47]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  P. V. van Diest,et al.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment , 2002, British Journal of Cancer.

[49]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Noh,et al.  Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  Y. Seo,et al.  Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. , 2000, Anticancer research.

[52]  P. Andersen,et al.  Factors influencing the effect of age on prognosis in breast cancer: population based study , 2000, BMJ : British Medical Journal.

[53]  G. Landberg,et al.  Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. , 1996, British Journal of Cancer.

[54]  Takuji Iwase,et al.  Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy , 2013, Breast Cancer.

[55]  M. Fernö,et al.  Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer , 2011, Breast Cancer Research and Treatment.